A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)

Trial Profile

A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms ESTEEM
  • Sponsors Biogen
  • Most Recent Events

    • 28 Oct 2017 Results (n=2011) of post-hoc analysis assessing annualised relapse rate, presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
    • 28 Apr 2017 1-year safety and efficacy results (n=2025; as of 12 Apr 2017), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 06 Apr 2017 Planned End Date changed from 1 Feb 2022 to 28 Feb 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top